TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Recent ESUS (between 7 days and 6 months), defined as:~* Recent ischemic stroke (including transient ischemic attack with positive neuroimaging) visualized by brain imaging that is not lacunar, and~* Absence of cervical carotid atherosclerotic stenosis\> 50% or occlusion, and~* No atrial fibrillation after ≥ 24-hour cardiac rhythm monitoring, and~* No intra-cardiac thrombus on either transesophageal or transthoracic echocardiography, and~* No other specific cause of stroke (for example, arteritis, dissection, migraine/vasospasm, drug abuse)~Exclusion Criteria:~* Severely disabling stroke (modified Rankin score ≥4)~* Indication for chronic anticoagulation or antiplatelet therapy~* Estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m\^2

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban (Type: EXPERIMENTAL): Rivaroxaban 15 mg orally once daily
- Aspirin (Type: ACTIVE_COMPARATOR): Aspirin 100 mg orally once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Intra-vaginal Culture of Embryos to In-vitro Culture of Embryos With Minimal Stimulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Normal uterine cavity~* One or more years of infertility~* Normal male partner semen analysis~Exclusion Criteria:~* Age \<18 years old or \>37 years old~* Antral Follicle Count (AFC) \<8~* Abnormal male partner semen analysis or use of donor sperm~* Vaginal inflammation or genital (vaginal, uterine, tubal) infection~* Uncontrolled chronic disease (such as uncontrolled diabetes or hypertension)~* Uterine anatomic abnormalities~* Allergy to plastics or inability to use diaphragm retention device~* Untreated hydrosalpinx~* Current alcohol abuse (defined by \>14 drinks/week)~* Prior history of IVF cycle where fertilization did not occur~* History of recurrent pregnancy loss

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 37 Years
- Healthy Volunteers: t

Study Arms:
- Intra-vaginal culture - INVOcell device (Type: EXPERIMENTAL): 3 day intra-vaginal incubation using the INVOcell device
- Traditional IVF culture (Type: ACTIVE_COMPARATOR): 3 day traditional IVF incubation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Infrared Thermography in Finding Skin Lesions in Patients With Kaposi's Sarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Meets 1 of the following criteria:~  * Histologically confirmed cutaneous Kaposi's sarcoma (KS)~    * At least one skin lesion accessible for imaging~   * HIV positivity with proven cutaneous KS and concurrent visceral or mucous membrane involvement allowed~ * Healthy volunteer (regardless of HIV status) (control)~PATIENT CHARACTERISTICS:~Performance status~* Not specified~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* Not specified~Renal~* Not specified~Other~* Pregnancy allowed~PRIOR CONCURRENT THERAPY:~* Prior topical, intralesional, or systemic treatment allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Aspirin as a Novel Anti-Inflammatory Modality in the Fontan Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults who have Fontan repair of single ventricle~Exclusion Criteria: Persons with the following history, conditions, or behavior will be excluded~* Active protein losing enteropathy within the past three years~* Congestive heart failure~* Active arrhythmias~* Taking Coumadin (Warfarin)~* Bleeding disorder~* Known esophageal varicies~* Consuming more than 10 alcoholic drinks per week.~* Pregnant~* Planning to become pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention: aspirin (Type: EXPERIMENTAL): 650 mg. Twice a day for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Does Inhaled Busedonide or Fluticasone Impair Adrenal Function?

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients receiving inhaled busedonide or fluticasone at daily dose of 200-800 mcg ' for at least 4 weeks~Exclusion Criteria:~* patients receiving any corticosteroid therapy, except inhaled busedonide or fluticasone.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, aged more than 18 years,~* Strongly suspected of having renal arterial disease,~* Scheduled (or to be scheduled) to undergo arterial catheter-based X-ray angiography examination,~Exclusion Criteria:~* Known grade IV or V chronic kidney disease (GFR\<30 mL/min/1.73m²),~* Contraindication to MRI,~* Acute renal dysfunction within the 6 months preceding Dotarem®-enhanced MRA examination,

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dotarem (Type: EXPERIMENTAL): Each subject will receive one injection of Dotarem 0.2 ml/kg.
- Time Of Flight Magnetic Resonance Angiography (Type: OTHER): Each subject undergo a TOF MRA

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fascia Iliaca Block for Post-Operative Pain Control After Total Hip Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* anterior approach total hip arthroplasty (THA) for unilateral osteoarthritis~* English-speaking~* age 18 to 75 years~* American Society of Anesthesiologists (ASA) physical status 1 to 3~* BMI \< 40 kg/m2~* Minimum weight of 50 kg.~* No contraindications to study procedures~Exclusion Criteria:~* Hip revision surgery~* Allergy to local anesthetics~* Allergy to oxycontin~* Allergy to pregabalin~* Allergy to fentanyl~* Allergy to midazolam~* Allergy to hydromorphone~* BMI \> 40 kg/m2~* Chronic pre-operative opioid use

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ropivacaine block (Type: ACTIVE_COMPARATOR): Ropivacaine 0.375% as a one-time 60 milliliter injection.
- saline block (Type: PLACEBO_COMPARATOR): Sodium chloride 0.9% as a one-time 60 milliliter injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-α Status in Patients With Metastatic Breast Cancer HER2 + and ERα Neg Treated With Trastuzumab + Pertuzumab + Taxane.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years.~2. Patient with metastatic breast cancer HER2 + (IHC+++ and/or HER2 amplification in ISH according to ASCO recommendations), ERα neg (0% in IHC) and Progesterone Receptor neg (0% in IHC).~3. Patient eligible according to the investigator for a treatment with trastuzumab + pertuzumab + taxane in the metastatic first line.~4. Available biopsy of a tumor lesion (archived material) or biopsiable tumor lesion for study (primitive tumor or metastasis other than bone).~5. OMS ≤ 2.~6. For non-menopausal patients, use of an effective contraceptive method at entry into the study and for the duration of the study.~7. Patient affiliated to a Social Health Insurance in France.~8. Patient must provide written informed consent prior to any study specific procedures.~Exclusion Criteria:~1. Any previous treatment for metastatic disease.~2. Prior adjuvant treatment with anti-HER2 antibodies taken within 6 months.~3. Patient with isolated hepatic metastasis.~4. Patient with hemostasis disorders.~5. Unbalanced Diabetes.~6. Patient with usual formal contraindication to PET/TDM Imaging.~7. Patient who has already started trastuzumab + pertuzumab + taxane treatment.~8. Pregnant or breastfeeding women.~9. Any psychological, familial, geographical or sociological condition which does not allow to respect the medical follow-up and/or compliance to study procedure.~10. Patient protected by law.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with metastatic breast cancer (Type: OTHER): Patients with metastatic breast cancer treated with trastuzumab + pertuzumab + taxane in the metastatic first line.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Noninvasive Biomarkers for Monitoring Cardiometabolic Risk in Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participating in the CARDIAC Boot Camp Program~* Between the ages of 4 and 17~* Parental permission~* Ability to provide assent~Exclusion Criteria:~* Inability to comply with saliva collection procedures~* Renal insufficiency or juvenile gout

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Severe Acute Respiratory Syndrome-Coronavirus-2 and Loss of Autonomy in the Elderly

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 70 years of age or older;~* Hospitalized in a short stay or a rehabilitation geriatric wards at one of the participating centers;~* Positive by Reverse Transcriptase-Polymerase Chain Reaction for severe acute respiratory syndrome (SARS-CoV-2) coronavirus or be considered to have SARS-CoV-2 coronavirus based on lung CT data and physician opinion;~* Formal consent to answer the questionnaire or, in the event of inability to give consent, consent obtained from the trusted third party;~* Affiliation to a social security scheme.~Exclusion Criteria:~* Patient under formal guardianship or trusteeship.

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of a Self-Retaining Pannus Retractor in Obese Patients Undergoing Cesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women with a BMI greater than or equal to 30 kg/m squared, aged 14-50 years old, undergoing non-emergent cesarean section for delivery and require pannus displacement for surgery.~Physicians Inclusion would include any physician who routinely perform C-sections~Exclusion Criteria:~* Patients undergoing emergency Cesarean-section Pre-existing concurrent infection including chorioamnionitis State of immunosuppression (ie. HIV, cancer) Long-term steroid use (\>2 days) Patients with a BMI \<30 kg/m2, or those with a BMI \>/=30kg who do not require pannus retraction.~If there is a rash in the area of retraction Adhesive/tape allergy. Physicians exclusion would include any physician who does not routinely perform C-sections.

- Gender: FEMALE
- Minimum Age: 14 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: ACTIVE_COMPARATOR): Subjects will receive use of the Traxi pannus retractor when undergoing cesarean section
- Standard (Type: NO_INTERVENTION): Patients will receive use of the standard of care option which is the montgomery straps

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Repeat Emergency Department Visits Among Patients With Asthma and COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Treated in the ED at the Erie County Medical Center (ECMC) for acute symptoms of asthma or COPD during the study period~* Patient age ≥ 18 years~* Resident of the City of Buffalo or Erie County~* Discharged to home~* Patient expresses willingness to return to ECMC or own primary care provider for follow-up visits~* Able to provide informed consent~* Able to comprehend English language~Exclusion Criteria:~* Received oral or inhaled corticosteroids in the week before ED presentation~* Presented to the ED primarily for prescription refills~* Complicated comorbid conditions (e.g. renal disease, cardiovascular disease, CHF, HIV)~* Admitted to ECMC or discharged to another facility~* Previously enrolled during a prior visit to the ED during the study period~* For female patients--pregnant or pregnancy status indeterminate~* Antibiotics are prescribed to treat current asthma/COPD exacerbation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care (Type: ACTIVE_COMPARATOR): Standard of Care: 30 day albuterol inhaler plus non-tapering course of oral prednisone (50 mg/d) for 4 days (1st dose will have been given in the ED)~Spacers will be dispensed with all multiple dose inhalers (MDI) to promote proper use and administration of inhaled medications.
- Treatment (Type: EXPERIMENTAL): Treatment: 30 day QVAR® (beclamethasone dipropionate) inhaler (80 mcg, 1 puff twice daily) plus 30 day albuterol inhaler plus non-tapering course of oral prednisone (50 mg/d) for 5 days~Spacers will be dispensed with all multiple dose inhalers (MDI) to promote proper use and administration of inhaled medications.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of PKs of 17-Beta-Estradiol Via Sublingual Placement Versus Swallowing in Male-to-Female Transgender Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* English speaker~* Currently taking 17-beta-estradiol tablet daily via sublingual or oral route on dose therapeutic for gender-affirming therapy; steady dose for at least 4 weeks~* Serum estradiol and testosterone levels within target therapeutic range (75-200 pg/mL and \<55 ng/dL, respectively)~Exclusion Criteria:~* Active or history of deep venous thrombosis/pulmonary embolism~* Active or recent (within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction)~* Liver dysfunction~* History of breast cancer~* History of orchiectomy~* Known sensitivity or allergy to any components of the study medication~* Taking potent CYP3A4 inhibitors or inducers

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- PO then SL (Type: ACTIVE_COMPARATOR): Subjects will administer 17-beta-estradiol orally (PO) for Study Day 1-14, followed by administration of 17-beta-estradiol sublingually (SL) for Study Day 15-28.
- SL then PO (Type: ACTIVE_COMPARATOR): Subjects will administer 17-beta-estradiol sublingually (SL) for Study Day 1-14, followed by administration of 17-beta-estradiol orally (PO) for Study Day 15-28.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Trial of Nabilone for the Treatment of Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Obese adults (BMI \> 30.0 kg/m2).~* For the optional imaging component of the study, a maximum weight (315 lbs) and a maximum girth in line with capacity of the machine (60 cm horizontal and 45 cm vertical; therefore, circumference of scanner is 166.6 cm)~* For women of reproductive potential (WORP) and men whose sexual partners are WORP: use of adequate methods of contraception (effective barrier methods such as male condoms, female condoms, cervical caps, diaphragms, or contraceptive sponges; and highly effective methods of contraception such as oral hormonal contraceptives, intrauterine devices (IUDs), vasectomy, or tubal ligation)~* AST/ALT, bilirubin, and kidney function tests within normal limits at screening.~Exclusion Criteria:~* Unstable gastrointestinal, respiratory, endocrinological, cardiovascular or cerebrovascular diseases that would prevent participation in the trial at QI (or its delegate) discretion,~* Unstable major psychiatric disorder(s) (i.e. Axis I Disorders) that would prevent participation in the trial at QI (or its delegate) discretion,~* Current substance use disorders (DSM-V) (excluding tobacco and caffeine),~* History of, or current neurological illnesses, that would prevent participation in the trial,~* Current use or use during the previous month of antipsychotic medications,~* Learning disability, amnesia or other conditions that impede memory and attention,~* Visual impairments that prevent participation in the study,~* Personal or family history of schizophrenia, or psychosis (or psychosis-related) disorders,~* Antibiotic use in the last 4 weeks,~* Previous bariatric surgery,~* Current use or use in the past month of other weight-loss pharmaceuticals,~* Cannabis use in last 6 months,~* Known sensitivity to cannabis or other cannabinoid agents,~* Pregnancy or lactation (females), and~* For the optional imaging component of the study:~  * Presence of metal implants or objects unsafe for MRI such as cardiac pacemakers, metal fragments in the eye, and aneurysm clips in your brain~ * Piercings or jewelry that are unable to be removed~ * Tattoos inked with metal dyes

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- Low-Dose Nabilone (Type: EXPERIMENTAL): pms-nabilone titrated to 2 mg daily
- High-Dose Nabilone (Type: EXPERIMENTAL): pms-nabilone titrated to 6 mg daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy